Hypervision Surgical, a startup developing real-time hyperspectral imaging for surgery, has raised £17 million in a Series A financing round led by Heal Capital, with participation from Angelini Ventures, IP Group, Daycrest, SINC Fund and Macmillan Cancer Support. The financing will accelerate commercial deployment of its Hyperspectral Intelligence® platform, expand clinical adoption, and advance development of its next-generation hyperspectral sensing technology co-developed with imec.
Despite advances in digital and robotic surgery, surgeons still rely largely on subjective visual assessment to guide intraoperative decisions. It addresses this limitation with a regulatory-cleared real-time hyperspectral imaging platform that delivers quantitative tissue insights beyond human vision. Its Hyperspectral Intelligence® platform combines on-chip spectral sensing, AI analytics and a cloud-scalable architecture to generate pixel-level insights into tissue physiology during surgery, transforming surgical imaging into data-driven decision support.
This architecture enables integration across open, minimally invasive, robotic and microscopic platforms, shifting surgical imaging from a hardware-limited model to a software-centric approach. Its first commercial system, HYPERSNAP®, is built on the NVIDIA IGX platform and provides continuous, dye-free measurement of tissue oxygenation while preserving natural colour. The system is certified in the United Kingdom and cleared by the US FDA for use in general surgery, with a new product code issued for AI and machine learning-based real-time video augmentation in surgical imaging.
By capturing spectral signatures invisible to the human eye, HYPERSNAP® enables real-time assessment of tissue viability during procedures such as bowel transection for cancer patients. Early clinical evaluations in colorectal surgery are underway in the United Kingdom, with initial results accepted for presentation at the SAGES Annual Meeting. The platform has also been selected for the FDA’s Safer Technologies Program, recognising its potential to improve the safety of existing surgical treatments.
This Series A marks a major milestone in our mission to power surgical intelligence through hyperspectral vision. By combining advanced spectral sensing with cloud-enabled AI analytics, we are building a new intelligence layer in surgery - giving surgeons real-time insights into tissue that were previously impossible to access.
Surgical AI has made impressive progress using conventional cameras, but it ultimately faces a ceiling - it captures how tissue looks, not what is happening beneath the surface. Hypervision removes that limitation by delivering real-time, quantitative insights into tissue physiology at the pixel level. We believe this represents the sensing layer on which the next generation of surgical systems will be built - one that will make surgery measurably safer. That’s why we are proud to lead this round.
The SAGES Investment Network Collaborative (SINC) is thrilled to have had the chance to review and join the investment opportunity that Hypervision represents. Enhancing the capabilities around non-contrast visualisation is truly a step forward in smarter imaging.
